Theravance Biopharma Valuation
| TBPH Stock | USD 8.58 0.10 1.18% |
At this time, the company appears to be undervalued. Theravance Biopharma has a current Real Value of $11.12 per share. The regular price of the company is $8.58. Our model measures the value of Theravance Biopharma from inspecting the company fundamentals such as Operating Margin of (0.77) %, return on equity of -0.16, and Shares Outstanding of 48.63 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Theravance Biopharma's valuation include:
Price Book 2.1909 | Enterprise Value 365.2 M | Enterprise Value Ebitda (9.69) | Price Sales 8.1266 | Forward PE 7.1839 |
Undervalued
Today
Please note that Theravance Biopharma's price fluctuation is not too volatile at this time. Calculation of the real value of Theravance Biopharma is based on 3 months time horizon. Increasing Theravance Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Theravance Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Theravance Stock. However, Theravance Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.58 | Real 11.12 | Target 13.4 | Hype 8.58 |
The intrinsic value of Theravance Biopharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Theravance Biopharma's stock price.
Estimating the potential upside or downside of Theravance Biopharma helps investors to forecast how Theravance stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theravance Biopharma more accurately as focusing exclusively on Theravance Biopharma's fundamentals will not take into account other important factors: When choosing an evaluation method for Theravance Biopharma, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Theravance Biopharma Investments |
|
Theravance Valuation Trend
Knowing Theravance Biopharma's actual value is paramount for traders to make sound investment determinations. Theravance Biopharma's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Theravance Biopharma's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Theravance Biopharma's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Theravance Market Cap
Theravance Biopharma is rated second in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 2.34 Billion. Theravance Biopharma retains roughly 417.27 Million in market capitalization claiming about 18% of equities under Health Care industry.Theravance Biopharma Total Value Analysis
Theravance Biopharma is at this time projected to have valuation of 365.2 M with market capitalization of 417.27 M, debt of 45.24 M, and cash on hands of 132.85 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Theravance Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 365.2 M | 417.27 M | 45.24 M | 132.85 M |
Theravance Biopharma Investor Information
About 85.0% of the company shares are owned by institutional investors. The book value of Theravance Biopharma was at this time reported as 4.22. The company recorded a loss per share of 0.89. Theravance Biopharma had not issued any dividends in recent years. Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. Theravance Bio is traded on NASDAQ Exchange in the United States. To find out more about Theravance Biopharma contact Rick MBA at 650 808 6000 or learn more at https://www.theravance.com.Theravance Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theravance Biopharma has an asset utilization ratio of 15.03 percent. This signifies that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Theravance Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Theravance Biopharma Ownership Allocation
The majority of Theravance Biopharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Theravance Biopharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Theravance Biopharma. Please pay attention to any change in the institutional holdings of Theravance Biopharma as this could imply that something significant has changed or is about to change at the company.Theravance Biopharma Profitability Analysis
The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M).About Theravance Biopharma Valuation
The stock valuation mechanism determines the current worth of Theravance Biopharma on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Theravance Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Theravance Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Theravance Biopharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Theravance Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Theravance Biopharma. We calculate exposure to Theravance Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Theravance Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 51.4 M | 53.9 M | |
| Pretax Profit Margin | (0.86) | (0.90) | |
| Operating Profit Margin | (0.93) | (0.97) | |
| Net Loss | (0.96) | (1.01) | |
| Gross Profit Margin | 0.89 | 0.94 |
8 Steps to conduct Theravance Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Theravance Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Theravance Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Theravance Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Theravance Biopharma's revenue streams: Identify Theravance Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Theravance Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Theravance Biopharma's growth potential: Evaluate Theravance Biopharma's management, business model, and growth potential.
- Determine Theravance Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Theravance Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Theravance Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 55.3 M | |
| Forward Price Earnings | 7.1839 |
Theravance Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Theravance Biopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Theravance we look at many different elements of the entity such as Theravance's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Theravance Biopharma's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Theravance Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Theravance Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Theravance Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Theravance Biopharma's worth.Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |